| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 176,7 k € | -86.1% | 1,3 M € | -97.3% | 46,6 M € | +9210.3% | 500,0 k € | — | — | — | ||||
| Gross margin | — | — | — | — | -3,8 M € | -0.5% | -3,8 M € | -164.8% | -1,4 M € | |||||
| EBITDA | -949,2 k € | +92.1% | -12,0 M € | -137.4% | 32,1 M € | +315.7% | -14,9 M € | -55.4% | -9,6 M € | -13.0% | -8,5 M € | -167.9% | -3,2 M € | |
| Operating profit | -19,5 M € | -53.8% | -12,7 M € | -140.5% | 31,3 M € | +299.0% | -15,7 M € | -51.8% | -10,4 M € | -11.3% | -9,3 M € | -148.8% | -3,7 M € | |
| Profit/loss | -17,4 M € | -53.6% | -11,3 M € | -136.4% | 31,1 M € | +299.7% | -15,6 M € | -58.2% | -9,9 M € | -11.1% | -8,9 M € | -153.6% | -3,5 M € | |
| Equity | 33,3 M € | -34.3% | 50,6 M € | +114.8% | 23,6 M € | +411.7% | -7,6 M € | -194.2% | 8,0 M € | -23.0% | 10,4 M € | +34.7% | 7,7 M € | |
| Total assets | 37,8 M € | -31.1% | 54,8 M € | +24.6% | 44,0 M € | +224.6% | 13,5 M € | -22.5% | 17,5 M € | +24.5% | 14,0 M € | +46.0% | 9,6 M € | |
| Cash | 6,2 M € | +21.3% | 5,1 M € | -26.8% | 6,9 M € | +96.9% | 3,5 M € | -67.2% | 10,7 M € | +47.3% | 7,3 M € | +14.0% | 6,4 M € | |
| Debts | 3,4 M € | +28.9% | 2,7 M € | -84.6% | 17,3 M € | -3.6% | 17,9 M € | +110.6% | 8,5 M € | +643.0% | 1,1 M € | +33.4% | 858,5 k € | |
| Staff | 59 | 52 | 45,9 | 58,1 | 55,4 | 50,1 | 21,3 | |||||||
Public limited company · Gent · incorporated on 11/06/2015 · 59,0 ETP
Public limited company loss-making in the latest fiscal year. Cash position rising (+21.3%).
Solid counterparty for a standard engagement.
Confo Therapeutics is a Public limited company incorporated in 2015. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Gent. It employs on average 59,0 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette